© 2022 MJH Life Sciences and AJMC. All rights reserved.
© 2022 MJH Life Sciences™ and Clinical Care Targeted Communications, LLC. All rights reserved.
January 18, 2022
Carl Schmid shares steps that providers and payers can take to overcome access barriers for HIV PrEP therapy.
Sean E. Bland, JD, discusses barriers to access for eligible patients to receive HIV PrEP therapy.
January 17, 2022
A brief review of disease and patient factors that influence the selection of therapy for myelodysplastic syndromes.
Reflections on the historical use of ESAs and blood transfusions to treat patients with myelodysplastic syndromes.
January 11, 2022
Carl Schmid and Frank J. Palella, MD, review unmet needs for the uptake of HIV PrEP therapy for at-risk patient populations.
Frank J. Palella, MD, and Ryan Bitton, PharmD, MBA, provide insight on the typical patient journey for someone who is going to receive HIV PrEP therapy and the recent increase in use of the therapy.
January 10, 2022
Experts consider shortcomings in the identification and management of myelodysplastic syndromes.
Practical perspectives on how to communicate MDS subclassifications with affected patients and caregivers.
January 04, 2022
Expert perspectives on the changes in MDS subclassifications as understandings of the disease have evolved.
January 03, 2022
Shared insight on how to best educate patients and caregivers on the broad nature of myelodysplastic syndromes.